Research theme for competitive and other funds (13):
2023 - 2026 変異受容体型チロシンキナーゼの細胞内輸送制御による白血病治療薬の開発研究
2022 - 2025 治癒を目指したCML幹細胞の特性解析
2020 - 2023 多発性骨髄腫の病態形成に関わる抗腫瘍免疫機構の解析研究
2018 - 2021 Characterization molecular and immunologic features of CML stem cells for treatment-free remission.
2016 - 2019 Analysis of novel pathogenesis caused by disorder of immature hematopoietic cells in multiple myeloma
2015 - 2018 Development of novel anti-leukemic therapy targeting clathrin-dependent endocytosis
2014 - 2017 The role of SATB1-MS4A3 in the differentiation of hematopoietic stem cells
2013 - 2016 Novel therapeutic approaches targeting intracellular trafficking of RTK mutants in acute myeloid leukemia cells.
2010 - 2012 Analysis of the roles of anamorsin, anti-apoptotic molecule, onsurvival and proliferation of B lymphocytes
2010 - 2011 Analysis of leukemogenic transgenic mice generated by tetraploid embryonic complementation method using Tet-off system.
2009 - 2010 Effects of iron-overload on normal hematopoiesis and disease progression of hamatological malignancies
2006 - 2007 造血器腫瘍の発生及び癌転移におけるNF-κBの機能解析とその制御
2003 - 2004 細胞周期制御因子による細胞増殖と死の制御機構
Show all
Papers (177):
Hayato Kaida, Takaaki Chikugo, Hirokazu Tanaka, Kazunari Ishii. 18 F-FDG Uptake in Pancreatic AL Amyloidosis Associated With Multiple Myeloma. Clinical nuclear medicine. 2024. 49. 8. 781-783
Yutaka Shimazu, Junya Kanda, Yoshiyuki Onda, Shin-Ichi Fuchida, Kensuke Ohta, Yuji Shimura, Satoru Kosugi, Ryosuke Yamamura, Mitsuhiro Matsuda, Hitoshi Hanamoto, et al. The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients. Cancer immunology, immunotherapy : CII. 2024. 73. 7. 135-135
Ayumi Kondo, Hirokazu Tanaka, Shinya Rai, Hiroshi Shima, Itaru Matsumura, Toshio Watanabe. Depletion of Ppp6c in hematopoietic and vascular endothelial cells causes embryonic lethality and decreased hematopoietic potential. Experimental hematology. 2024. 133. 104205-104205
Naokazu Nakamura, Nobuyoshi Arima, Teruhito Takakuwa, Satoshi Yoshioka, Kazunori Imada, Kentaro Fukushima, Masaaki Hotta, Shin-Ichi Fuchida, Junya Kanda, Nobuhiko Uoshima, et al. Efficacy of elotuzumab for multiple myeloma deteriorates after daratumumab: a multicenter retrospective study. Annals of hematology. 2024
Yuji Shimura, Hirohiko Shibayama, Aya Nakaya, Ryosuke Yamamura, Kazunori Imada, Hitomi Kaneko, Hitoshi Hanamoto, Shin-Ichi Fuchida, Hirokazu Tanaka, Satoru Kosugi, et al. Real-world data on induction therapy in patients with transplant-ineligible newly diagnosed multiple myeloma: retrospective analysis of 598 cases from Kansai Myeloma Forum. International journal of hematology. 2023
Aya Nakaya, Takae Kohara, Hirohiko Shibayama, Yoshiyuki Onda, Junya Kanda, Hitomi Kaneko, Kazunori Imada, Toru Kida, Satoru Kosugi, Jun Ishikawa, et al. Retrospective Multi-center Study of Adolescent and Young Adult (AYA) Multiple Myeloma in Kansai Myeloma Forum Registry. BONE MARROW TRANSPLANTATION. 2020. 55. SUPPL 1. 560-561
岩田 吉生, 森田 泰慶, 辻 潔, 頼 晋也, 田崎 貴之, 井上 宏昭, 谷口 康博, 藤本 昂, 田中 宏和, 芦田 隆司, et al. 脳静脈洞血栓症を合併し、開頭減圧術・術後エクリズマブ投与が有効であったPNHの一例(Post-operative treatment with eculizumab for PNH presenting as cerebral venous sinus thrombosis). 臨床血液. 2018. 59. 9. 1765-1765
藤原 亮介, 田中 宏和, 芹澤 憲太郎, 金子 仁臣, 志村 勇司, 太田 健介, 淵田 真一, 中谷 綾, 諫田 淳也, 八木 秀男, et al. KMFに登録されたボルテゾミブとIMiDs両剤に抵抗性の再発骨髄腫の予後解析(Clinical outcomes of relapsed myeloma, dual refractory to bortezomib and IMiDs in KMF registry). 臨床血液. 2018. 59. 9. 1739-1739
Recent trends in basic research on myeloma initiating cells.
2022
Novel therapeutic approach for leukemic stem cells
2011
Lectures and oral presentations (98):
Gilteritinib treatment for extramedullary relapse of FLT3-ITD acute myeloid leukemia
(日本造血細胞移植学会総会プログラム・抄録集 2021)
Clinical usefulness of Letermovir for patients with stem cell transplantation
(日本造血細胞移植学会総会プログラム・抄録集 2021)
CMML様の病型移行を来したMDSに対してアザシチジンが有効であった1例
(臨床血液 2021)
Retrospective Multi-center Study of Adolescent and Young Adult (AYA) Multiple Myeloma in Kansai Myeloma Forum Registry
(BONE MARROW TRANSPLANTATION 2020)
Outcomes of allo-SCT for patients in non-remission especially with chemoresistance
(日本造血細胞移植学会総会プログラム・抄録集 2020)
1989 - 1995 Hamamatsu University School of Medicine
Professional career (1):
医学博士 (大阪大学)
Work history (1):
2023/04 - 現在 Kindai University Faculty of Medicine Department of Medicine
Association Membership(s) (5):
American Society of Hematology
, THE JAPAN SOCIETY OF TRANSFUSION MEDICINE AND CELL THERAPY
, THE JAPAN SOCIETY FOR TRANSPLANTATION
, THE JAPANESE SOCIETY OF HEMATOLOGY
, THE JAPANESE SOCIETY OF INTERNAL MEDICINE